Longevity claims must be tested clinically, not just on social media
Maier emphasises benchmarks, trials and transparency — as opposed to hype without endpoints.
Maier emphasises benchmarks, trials and transparency — as opposed to hype without endpoints.
A multicentre RCT found NMN up to 900 mg/day safe in the short term, with effects on NAD+ and walking distance; long-term outcomes are lacking.
ACCURATE is investigating whether individual NMN adjustment optimises NAD+ better than standard dosing — results to follow.
The ‘What does the science say?’ rating is an estimate by the Engy editors based on the cited source and the wider research. Not medical advice.
With Maier too, the same applies: raising NAD+ is not proven life extension. Commercial longevity clinics and consumer products are moving faster than the trials.
Her public role balances scientific caution with visibility in a hype-driven market — something readers should keep a close eye on.